mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer (Q38973649)

8 September 2017

title

mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer (English)

1 reference

8 September 2017

1 reference

XianGuo Chen

1

1 reference

8 September 2017

HaiYan Cheng

2

1 reference

8 September 2017

TengFei Pan

3

1 reference

8 September 2017

Yi Liu

4

1 reference

8 September 2017

Yang Su

5

1 reference

8 September 2017

CuiPing Ren

6

1 reference

8 September 2017

DaKe Huang

7

1 reference

8 September 2017

XiaoJun Zha

8

1 reference

8 September 2017

ChaoZhao Liang

9

1 reference

8 September 2017

language of work or name

1 reference

7 July 2014

1 reference

8 September 2017

published in

Molecular Carcinogenesis

1 reference

8 September 2017

volume

54

1 reference

8 September 2017

issue

10

1 reference

8 September 2017

page(s)

1086-1095

1 reference

8 September 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Epithelial-mesenchymal transitions in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Epithelial-mesenchymal transitions in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Complex networks orchestrate epithelial-mesenchymal transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

The fallacy of epithelial mesenchymal transition in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Dual roles of E-cadherin in prostate cancer invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

mTOR signaling in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

BMK1 kinase suppresses epithelial-mesenchymal transition through the Akt/GSK3β signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Rho and Rac take center stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Cell migration: Rho GTPases lead the way

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Rac activation and inactivation control plasticity of tumor cell movement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Prostatic intra-epithelial neoplasia and early invasion in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Transcriptional regulation of cell polarity in EMT and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Pulsed contractions of an actin-myosin network drive apical constriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

RhoA and microtubule dynamics control cell-basement membrane interaction in EMT during gastrulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Snail regulates cell-matrix adhesion by regulation of the expression of integrins and basement membrane proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Mammalian target of rapamycin and Rictor control neutrophil chemotaxis by regulating Rac/Cdc42 activity and the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

mTOR Complex Component Rictor Interacts with PKCζ and Regulates Cancer Cell Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Mammalian Rho GTPases: new insights into their functions from in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMC.22177

21 January 2018

Identifiers

DOI

10.1002/MC.22177

1 reference

8 September 2017

1 reference